Literature DB >> 35731887

B cell targeting in CAR T cell therapy: Side effect or driver of CAR T cell function?

Gregory M Chen1, Jan Joseph Melenhorst2,3,4,5,6, Kai Tan3,5,7,8.   

Abstract

Chimeric antigen receptor (CAR) T cell therapies targeting CD19 and CD22 have been successful for treating B cell cancers, but CAR T cells targeting non-B cell cancers remain unsuccessful. We propose that rather than being strictly a side effect of therapy, the large number of CAR interactions with normal B cells may be a key contributor to clinical CAR T cell responses.

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35731887      PMCID： PMC9284935          DOI： 10.1126/scitranslmed.abn3353

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN： 1946-6234            Impact factor:   19.319


  47 in total

1.  Treatment of advanced leukemia in mice with mRNA engineered T cells.

Authors:  David M Barrett; Yangbing Zhao; Xiaojun Liu; Shuguang Jiang; Carmine Carpenito; Michael Kalos; Richard G Carroll; Carl H June; Stephan A Grupp
Journal:  Hum Gene Ther       Date:  2011-09-23       Impact factor: 5.695

2.  Modulation of Target Antigen Density Improves CAR T-cell Functionality and Persistence.

Authors:  Sneha Ramakrishna; Steven L Highfill; Zachary Walsh; Sang M Nguyen; Haiyan Lei; Jack F Shern; Haiying Qin; Ira L Kraft; Maryalice Stetler-Stevenson; Constance M Yuan; Jennifer D Hwang; Yang Feng; Zhongyu Zhu; Dimiter Dimitrov; Nirali N Shah; Terry J Fry
Journal:  Clin Cancer Res       Date:  2019-05-20       Impact factor: 12.531

Review 3.  How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies.

Authors:  Joshua A Hill; Susan K Seo
Journal:  Blood       Date:  2020-08-20       Impact factor: 22.113

4.  A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors.

Authors:  Xiaojun Liu; Raghuveer Ranganathan; Shuguang Jiang; Chongyun Fang; Jing Sun; Soyeon Kim; Kheng Newick; Albert Lo; Carl H June; Yangbing Zhao; Edmund K Moon
Journal:  Cancer Res       Date:  2016-03-15       Impact factor: 12.701

Review 5.  Do most lymphocytes in humans really reside in the gut?

Authors:  Vitaly V Ganusov; Rob J De Boer
Journal:  Trends Immunol       Date:  2007-10-26       Impact factor: 16.687

6.  4-1BB costimulation promotes CAR T cell survival through noncanonical NF-κB signaling.

Authors:  Benjamin I Philipson; Roddy S O'Connor; Michael J May; Carl H June; Steven M Albelda; Michael C Milone
Journal:  Sci Signal       Date:  2020-03-31       Impact factor: 8.192

7.  Antigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR T cells.

Authors:  Nathan Singh; Noelle V Frey; Boris Engels; Shannon L Maude; Saar Gill; Marco Ruella; David M Barrett; Olga Shestova; Pranali Ravikumar; Katherine D Cummins; Yong Gu Lee; Raymone Pajarillo; Inkook Chun; Amy Shyu; Steven L Highfill; Andrew Price; Linlin Zhao; Liaomin Peng; Brian Granda; Melissa Ramones; Xueqing Maggie Lu; David A Christian; Jessica Perazzelli; Simon F Lacey; Nathan H Roy; Janis K Burkhardt; Florent Colomb; Mohammad Damra; Mohamed Abdel-Mohsen; Ting Liu; Dongfang Liu; Daron M Standley; Regina M Young; Jennifer L Brogdon; Stephan A Grupp; Carl H June
Journal:  Nat Med       Date:  2021-04-22       Impact factor: 53.440

8.  Viral immune evasion due to persistence of activated T cells without effector function.

Authors:  A J Zajac; J N Blattman; K Murali-Krishna; D J Sourdive; M Suresh; J D Altman; R Ahmed
Journal:  J Exp Med       Date:  1998-12-21       Impact factor: 14.307

9.  Induction and exhaustion of lymphocytic choriomeningitis virus-specific cytotoxic T lymphocytes visualized using soluble tetrameric major histocompatibility complex class I-peptide complexes.

Authors:  A Gallimore; A Glithero; A Godkin; A C Tissot; A Plückthun; T Elliott; H Hengartner; R Zinkernagel
Journal:  J Exp Med       Date:  1998-05-04       Impact factor: 14.307

10.  Effective combination immunotherapy using oncolytic viruses to deliver CAR targets to solid tumors.

Authors:  Anthony K Park; Yuman Fong; Sang-In Kim; Jason Yang; John P Murad; Jianming Lu; Brook Jeang; Wen-Chung Chang; Nanhai G Chen; Sandra H Thomas; Stephen J Forman; Saul J Priceman
Journal:  Sci Transl Med       Date:  2020-09-02       Impact factor: 19.319
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.